InvestorsObserver
×
News Home

Do Analysts Expect BridgeBio Pharma Inc (BBIO) Stock to Rise After It Has Risen 3.87% in a Month?

Friday, September 17, 2021 10:45 AM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect BridgeBio Pharma Inc (BBIO) Stock to Rise After It Has Risen 3.87% in a Month?

Analysts who follow BridgeBio Pharma Inc (BBIO) on average expect it to gain 56.90% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns BBIO an Analyst Ranking of 73, which means it ranks higher than 73 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.9
Wall Street analysts are rating BBIO a Strong Buy today. Find out what this means to you and get the rest of the rankings on BBIO!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With BridgeBio Pharma Inc Stock Today?

BridgeBio Pharma Inc (BBIO) stock has risen 2.32% while the S&P 500 has fallen -0.74% as of 10:43 AM on Friday, Sep 17. BBIO has risen $1.15 from the previous closing price of $49.36 on volume of 191,619 shares. Over the past year the S&P 500 is higher by 32.29% while BBIO has risen 31.33%. BBIO lost -$3.82 per share the over the last 12 months. Click Here to get the full Stock Report for BridgeBio Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App